PPI无应答者动态反流监测的临床作用:推荐声明
该推荐声明采用RAND Appropriateness Method,由17位专家经讨论、修订和两轮排序,制定PPI无应答典型反流症状患者动态反流监测的推荐条款。声明涵盖96小时无线pH监测、酸暴露时间阈值及阻抗-pH监测在已证实GERD患者中的应用。
要点
- 未证实GERD且每日一次PPI仍有典型症状者,推荐96小时无线pH监测(停PPI)评估抑酸需求。
- 所有监测日AET<4.0%且反流-症状关联阴性可排除GERD,不支持继续PPI治疗。
- 已证实GERD者PPI期间阻抗-pH监测有助于定义难治性GERD及持续症状机制。
核心结论
- 针对典型反流症状且PPI无应答患者,已确定适用于平均临床诊疗的动态反流监测推荐声明。
研究设计与样本
- 采用RAND Appropriateness Method(RAM),17位专家参与讨论、修订及两轮推荐声明排序。
- 动态反流监测方案、方法学和阈值经≥80%专家组成员评为适当即符合适当性标准。
主要发现
- 未证实GERD且每日一次PPI仍有持续典型反流症状者,推荐96小时无线pH监测(停PPI)作为评估抑酸需求的适当诊断工具。
- 所有监测日AET<4.0%且反流-症状关联阴性可排除GERD,不支持继续PPI治疗。
- ≥2天AET>6.0%是GERD的确凿证据并支持GERD治疗,≥2天AET>10%提示严重酸负荷并支持升级抗反流治疗。
- 已证实GERD者PPI期间阻抗-pH监测有助于定义难治性GERD及持续症状机制。
- PPI期间阻抗-pH监测显示反流事件<40次、AET<2.0%且反流-症状关联阴性不支持升级抗反流治疗;AET>4.0%且反流-症状关联阳性支持升级抗反流治疗包括侵入性治疗。
关键数值与推荐
- 推荐96小时无线pH监测(停PPI)用于未证实GERD且每日一次PPI仍有典型症状者评估抑酸需求。
- 所有监测日AET<4.0%且反流-症状关联阴性可排除GERD,不支持继续PPI治疗。
- ≥2天AET>6.0%为GERD确凿证据并支持GERD治疗;≥2天AET>10%提示严重酸负荷并支持升级抗反流治疗。
- 已证实GERD者PPI期间阻抗-pH监测:反流事件<40次、AET<2.0%且关联阴性不支持升级治疗;AET>4.0%且关联阳性支持升级抗反流治疗包括侵入性治疗。
临床怎么用
- 对未证实GERD且每日一次PPI仍有典型反流症状者,可行96小时无线pH监测(停PPI)评估抑酸需求。
- 根据AET阈值及反流-症状关联判断是否排除GERD、继续或升级抗反流治疗。
- 已证实GERD者PPI期间阻抗-pH监测用于定义难治性GERD及持续症状机制。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Optimal ambulatory reflux monitoring methodology in symptomatic reflux patients continues to be debated. AIMS: To utilise published literature and expert opinion to develop recommendation statements addressing use of ambulatory reflux monitoring in clinical practice METHODS: The RAND Appropriateness Method (RAM) was utilised among 17 experts with discussion, revision and two rounds of ranking of recommendation statements. Ambulatory reflux monitoring protocol, methodology and thresholds ranked as appropriate by ≥80% of panellists met the criteria for appropriateness. RESULTS: Prolonged (96-h recommended) wireless pH monitoring off proton pump inhibitor (PPI) was identified as the appropriate diagnostic tool to assess the need for acid suppression in patients with unproven gastro-oesophageal reflux disease (GERD) and persisting typical reflux symptoms despite once-daily PPI. Acid exposure time (AET) <4.0% on all days of monitoring with negative reflux-symptom association excludes GERD and does not support ongoing PPI treatment. Conversely, AET >6.0% across ≥2 days is conclusive evidence for GERD and supports treatment for GERD, while AET >10% across ≥2 days identifies severe acid burden that supports escalation of anti-reflux treatment. In previously proven GERD, impedance-pH monitoring on PPI is helpful in defining refractory GERD and mechanisms of continued symptoms; the presence of <40 reflux events, AET <2.0% and a negative reflux-symptom association does not support escalation of anti-reflux treatment. In contrast, AET > 4.0% and positive reflux-symptom association support escalation of anti-reflux treatment, including use of invasive therapeutics. CONCLUSIONS: Statements meeting appropriateness for average clinical care have been identified when utilising reflux monitoring in patients with typical reflux symptoms and PPI non-response.
引用
- Yadlapati R, Gawron AJ, Gyawali CP, et al. Clinical role of ambulatory reflux monitoring in PPI non-responders: recommendation statements. Aliment Pharmacol Ther. 2022. PMID: 35971888. doi:10.1111/apt.17180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。